Forum Agenda
-
Keynote Forum: The Global Journey of China’s Innovation Drugs
-
-
Future-Driven Intelligent R&D–AI for Life Sciences and Drug Discovery
-
The Era of Superintelligent Agents for Chinese Innovative Drugs
-
Panel Discussion: AI-Empowered Four-in-One Translation Platform
-
AI-Driven Innovation Practices in Pharmaceutical Enterprises
-
AI·Intelligent Transformation: From Data Foundation to Scenario Value
-
-
Medicine-Engineering Integration and Innovative Medical Devices
-
Cross-Border Cooperation and China’s New Drug Global Expansion
-
Global Development of Pharma Enterprises and Emerging Market Cooperation
-
China-Japan Cooperation Session: Leveraging Japan’s Market to Boost Overseas Expansion Strategies
-
Legal Safeguard and Value Empowerment for Globalization of Chinese Pharma Enterprises
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
Global BD Cooperation Session for Innovative Drugs – Track 1, 2 & 3
-
Collaboration Between North American and Chinese Innovative Drug Industries
-
Biosimilars Commercialization & Global Launch Session(China Focus)
-
Protheragen Session: Global Biomedical Cross-Border Transactions
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
U.S. Biotech Tensions and the Future Road for Chinese Pharmaceutical Companies Going Global Session
-
July 22,14:00-17:40
ATMP & CGT Global Expansion Session
Stay tuned
Meeting Planning
Jinhua Zhang:Chairman & CEO, IASO Biotherapeutics
14:00-14:20 China's CAR-T Global Registration Practice: Internationalization Strategy, Regulatory Pathways, and Future Trends
Chunli Ren:Senior Vice President, Regulatory Affairs, IASO Biotherapeutics
14:20-14:40 AI-Powered, Life Without Borders – Challenges and Pathways to Breakthroughs in Global Cross-Border Supply of CGT
Wei Shi:COO, IASO Biotherapeutics
14:40-15:00 China's Cell and Gene Therapy Industry Through the Lens of ASGCT and ASCO
Jun Ma:Director, Harbin Institute of Hematology & Oncology
15:00-15:25 Dialogue Theme: Japan’s Regulatory System for Advanced Therapeutic Products: Approval Pathways and Future Outlook
Chunli Ren( Moderator):Senior Vice President, Regulatory Affairs, IASO Biotherapeutics
Yosuke Maruyama:Director, Regenerative Medical Products Review Division, PMDA, Japan
15:25-15:40 Break
15:40-16:20 Roundtable: Regulatory Innovation and International Collaboration of Cross-Border Supply Chains for ATMP & CGT Medicines
Wei Shi(Moderator):COO, IASO Biotherapeutics
Shanghai Customs (TBD)
Alva Wang:General Manager, Shanghai Pudong Global Outbound Comprehensive Service Center
Steven Fang:General Manager, China Eastern Airlines Cold Chain
Jibing Ju:Chairman, Shengsheng Logistics
16:20-17:00 Roundtable: Commercialization & Global Market Expansion
Yu Zhang(Moderator):Yu Zhang, Director & Co-President, Vcanbio
Shawn Xiang:CEO, BRL Medicine
Hua Zhang:CCO, IASO Biotherapeutics
Qing Gao:Chairman, HUASAIBIO
Zhimin Zhou:CEO, AlphaBiopharma
17:00-17:40 Dialogue Session:Hot Topics in Current CGT IndustryHot Topics in Current CGT Industry
Jinhua Zhang(Moderator):Founder, Chairman & CEO, IASO Biotherapeutics
Grace Zhou:Founder, Chairman & CEO, ImmVira